Piceatannol-3'-O-β-d-glucopyranoside mitigates myocardial ischemia-reperfusion injury by inhibiting ferroptosis through the regulation of NDUFS1 lactylation via metabolic reprogramming - PubMed
2 hours ago
- #Ferroptosis
- #Myocardial Ischemia-Reperfusion Injury
- #Metabolic Reprogramming
- Piceatannol-3'-O-β-d-glucopyranoside (PG) mitigates myocardial ischemia-reperfusion injury (MIRI) by inhibiting ferroptosis.
- PG improves cardiac function by enhancing LVEF and LVFS, reducing cTnI, CK-MB, ROS, lactate, and LDH levels, and increasing ATP expression.
- PG reduces lactate and pyruvate levels, as shown in metabolomics from clinical serum samples, and exogenous lactate weakens PG's cardioprotective effects.
- PG suppresses PDK4, MCT1, and ACSL4 protein expression while enhancing GPX4, inhibiting lipid peroxidation, and improving mitochondrial structure and function.
- Overexpression of PDK4 or NDUFS1 K170 lactylation impairs PG-mediated improvement in MIRI, indicating PG acts by inhibiting NDUFS1 lactylation via metabolic reprogramming.